Pertuzumab and Trastuzumab and Chemotherapy Therapy - 21 day cycle. NCCP National SACT Regimen. HSE.

Regulatory approval published by the Health Service Executive.

Citation

Pertuzumab and Trastuzumab and Chemotherapy Therapy - 21 day cycle, 2023, version number 3, NCCP National SACT Regimen, NCCP, viewed 01/09/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/350%20pertuzumab%20and%20trastuzumab%20and%20chemotherapy.pdf

View API

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication Statements
Pertuzumab in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence. 2

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Docetaxel, Pertuzumab, Trastuzumab
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Doxorubicin, Paclitaxel, Pertuzumab, Trastuzumab